Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 639 drug-target rows in SSL view, for TSG = PIK3R1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib PIK3R1 PARP1 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PIK3R1 ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PIK3R1 CTLA4 4
nivolumab, ipilimumab PIK3R1 CTLA4 4
paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5fu) + leucovorin (calcium folinate/folinic acid), durvalumab, tremelimumab, nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5fu) PIK3R1 CTLA4 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PIK3R1 ABL1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 WEE1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 FGFR4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 MAP2K1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3R1 BTK 3
biospecimen collection, computed tomography, echocardiography, ipilimumab, magnetic resonance imaging, nivolumab PIK3R1 CTLA4 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus PIK3R1 MTOR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan PIK3R1 FGFR4 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan PIK3R1 FGFR3 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PIK3R1 RXRB 3
pembrolizumab, belzutifan, lenvatinib PIK3R1 FGFR4 3
pembrolizumab, belzutifan, lenvatinib PIK3R1 FGFR3 3
abemaciclib PIK3R1 CDK6 7
everolimus PIK3R1 MTOR 7
ibrutinib PIK3R1 BTK 7
nintedanib PIK3R1 FGFR3 7
palbociclib PIK3R1 CDK6 7
pazopanib PIK3R1 FGFR3 7
regorafenib PIK3R1 ABL1 7
adavosertib, radiation therapy PIK3R1 WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PIK3R1 ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PIK3R1 MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel PIK3R1 FGFR3 2
alvocidib, paclitaxel PIK3R1 CDK9 2
alvocidib, paclitaxel PIK3R1 CDK6 2
bbi-355, erlotinib, futibatinib PIK3R1 FGFR4 2
bbi-355, erlotinib, futibatinib PIK3R1 FGFR3 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PIK3R1 ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment PIK3R1 BTK 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib PIK3R1 CDK6 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib PIK3R1 MAP2K1 2
bms-986207, nivolumab, ipilimumab PIK3R1 CTLA4 2
cft1946, trametinib, cetuximab PIK3R1 MAP2K1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study PIK3R1 MTOR 2
cobimetinib, mehd7945a PIK3R1 MAP2K1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel PIK3R1 CTLA4 2
durvalumab, tremelimumab, sbrt PIK3R1 CTLA4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab PIK3R1 CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib PIK3R1 JAK2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study PIK3R1 HDAC3 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study PIK3R1 HDAC2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a PIK3R1 FGFR4 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a PIK3R1 FGFR3 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib PIK3R1 JAK2 2
ipilimumab PIK3R1 CTLA4 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib PIK3R1 MAP2K1 2
lenvatinib, pembrolizumab PIK3R1 FGFR4 2
lenvatinib, pembrolizumab PIK3R1 FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate PIK3R1 FGFR4 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate PIK3R1 FGFR3 2
ly3022855, durvalumab, tremelimumab PIK3R1 CTLA4 2
mirdametinib, bgb-3245 PIK3R1 MAP2K1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PIK3R1 FGFR4 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a PIK3R1 FGFR3 2
motexafin gadolinium, radiation therapy PIK3R1 RRM2 2
nintedanib, pembrolizumab PIK3R1 FGFR3 2
nivolumab, ipilimumab, cobimetinib PIK3R1 CTLA4 2
nivolumab, ipilimumab, cobimetinib PIK3R1 MAP2K1 2
olaparib PIK3R1 PARP3 2
pembrolizumab, guadecitabine, mocetinostat PIK3R1 HDAC3 2
pembrolizumab, guadecitabine, mocetinostat PIK3R1 HDAC2 2
pembrolizumab, lenvatinib PIK3R1 FGFR4 2
pembrolizumab, lenvatinib PIK3R1 FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PIK3R1 FGFR4 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu PIK3R1 FGFR3 2
pembrolizumab, sonidegib PIK3R1 SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin PIK3R1 FGFR4 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin PIK3R1 FGFR3 2
pharmacological study, romidepsin PIK3R1 ABCC1 2
pharmacological study, romidepsin PIK3R1 HDAC4 2
pharmacological study, romidepsin PIK3R1 HDAC2 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery PIK3R1 FGFR3 2
regorafenib, laboratory biomarker analysis PIK3R1 ABL1 2
selumetinib, medi4736, tremelimumab PIK3R1 CTLA4 2
selumetinib, medi4736, tremelimumab PIK3R1 MAP2K1 2
stereotactic body radiotherapy, ipilimumab, nivolumab, pembrolizumab or atezolizumab PIK3R1 CTLA4 2
temsirolimus PIK3R1 MTOR 2
temsirolimus, laboratory biomarker analysis PIK3R1 MTOR 2
trabectedin, ipilimumab, nivolumab PIK3R1 CTLA4 2
bethanechol PIK3R1 CHRM1 7
binimetinib PIK3R1 MAP2K1 7
bosutinib PIK3R1 ABL1 7
entrectinib PIK3R1 JAK2 7
erdafitinib PIK3R1 FGFR4 7
erdafitinib PIK3R1 FGFR3 7
pemigatinib PIK3R1 FGFR3 7
ponatinib PIK3R1 ABL1 7
ribociclib PIK3R1 CDK6 7
romidepsin PIK3R1 HDAC2 7
ruxolitinib PIK3R1 JAK2 7
selumetinib PIK3R1 MAP2K1 7
trilaciclib PIK3R1 CDK6 7
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography PIK3R1 PARP3 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat PIK3R1 HDAC3 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat PIK3R1 HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat PIK3R1 HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat PIK3R1 HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide PIK3R1 RRM2 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) PIK3R1 MAP2K1 1
abemaciclib, abemaciclib PIK3R1 CDK6 1
abemaciclib, bevacizumab PIK3R1 CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf PIK3R1 CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine PIK3R1 CDK6 1
abemaciclib, ly3214996 PIK3R1 CDK6 1
abemaciclib, surgery PIK3R1 CDK6 1
adavosertib PIK3R1 WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy PIK3R1 WEE1 1
adavosertib, radiation therapy, temozolomide PIK3R1 WEE1 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy PIK3R1 HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid PIK3R1 HDAC2 1
aee788, everolimus PIK3R1 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PIK3R1 PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PIK3R1 ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PIK3R1 CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PIK3R1 BTK 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PIK3R1 MTOR 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib PIK3R1 MAP2K1 1
alpelisib, everolimus, exemestane PIK3R1 MTOR 1
alvocidib, docetaxel PIK3R1 CDK9 1
alvocidib, docetaxel PIK3R1 CDK6 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis PIK3R1 CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis PIK3R1 CDK6 1
anetumab ravtansine, biopsy, biospecimen collection, gemcitabine hydrochloride, ipilimumab, nivolumab PIK3R1 CTLA4 1
anti-sema4d monoclonal antibody vx15/2503, ipilimumab, nivolumab, surgery PIK3R1 CTLA4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib PIK3R1 CDK6 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib PIK3R1 SMO 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib PIK3R1 MTOR 1
arsenic trioxide PIK3R1 IKBKB 1
arsenic trioxide, radiation therapy PIK3R1 IKBKB 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy PIK3R1 IKBKB 1
atorvastatin, temozolomide, radiotherapy PIK3R1 HDAC2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab PIK3R1 DNMT1 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab PIK3R1 HDAC3 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab PIK3R1 HDAC2 1
azd1775, olaparib PIK3R1 PARP3 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus PIK3R1 MTOR 1
bethanechol, gemcitabine, nab-paclitaxel PIK3R1 CHRM1 1
bevacizumab, cediranib, cediranib maleate, olaparib PIK3R1 PARP3 1
bevacizumab, dasatinib, placebo PIK3R1 ABL1 1
bevacizumab, dasatinib, placebo PIK3R1 BTK 1
bevacizumab, everolimus, octreotide acetate PIK3R1 MTOR 1
bevacizumab, temozolomide, vorinostat PIK3R1 HDAC3 1
bevacizumab, temozolomide, vorinostat PIK3R1 HDAC2 1
bevacizumab, temsirolimus PIK3R1 MTOR 1
binimetinib, hydroxychloroquine PIK3R1 MAP2K1 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging PIK3R1 FGFR4 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging PIK3R1 FGFR3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib PIK3R1 PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab PIK3R1 PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, palbociclib PIK3R1 CDK6 1
biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib PIK3R1 SMO 1
biopsy, calaspargase pegol-mknl, cobimetinib PIK3R1 MAP2K1 1
biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration PIK3R1 PARP3 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography PIK3R1 FGFR4 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography PIK3R1 FGFR3 1
blu-222, carboplatin, ribociclib, fulvestrant PIK3R1 CDK6 1
bosutinib PIK3R1 MAP2K1 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab PIK3R1 CDK6 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab PIK3R1 FGFR3 1
cabozantinib, durvalumab, tremelimumab PIK3R1 CTLA4 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab PIK3R1 PARP3 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor PIK3R1 HDAC3 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor PIK3R1 HDAC2 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin PIK3R1 IKBKB 1
ceralasertib, olaparib, durvalumab PIK3R1 PARP3 1
chemotherapy, cladribine, radiation therapy PIK3R1 RRM2 1
chlorpromazine, temozolomide, radiation therapy PIK3R1 CHRM1 1
cobimetinib, hydroxychloroquine, atezolizumab PIK3R1 MAP2K1 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab PIK3R1 PARP3 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab PIK3R1 CTLA4 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab PIK3R1 MAP2K1 1
contrast-enhanced magnetic resonance imaging, ipilimumab, nivolumab, novottf-100a device, quality-of-life assessment, questionnaire administration, radiation therapy, temozolomide PIK3R1 CTLA4 1
conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy PIK3R1 RRM2 1
conventional surgery, laboratory biomarker analysis, sorafenib tosylate, temsirolimus PIK3R1 MTOR 1
cyclophosphamide, nivolumab, ipilimumab, gvax pancreas vaccine, crs-207, crs-207 PIK3R1 CTLA4 1
cytoreductive surgery, perifosine, temsirolimus PIK3R1 MTOR 1
dabrafenib, trametinib PIK3R1 MAP2K1 1
dabrafenib, trametinib, carboplatin, vincristine PIK3R1 MAP2K1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride PIK3R1 ABL1 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride PIK3R1 BTK 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method PIK3R1 ABL1 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method PIK3R1 BTK 1
dasatinib, laboratory biomarker analysis, physiologic testing PIK3R1 ABL1 1
dasatinib, laboratory biomarker analysis, physiologic testing PIK3R1 BTK 1
dasatinib, mfolfox6 PIK3R1 ABL1 1
dasatinib, mfolfox6 PIK3R1 BTK 1
dasatinib, pharmacological study PIK3R1 ABL1 1
dasatinib, pharmacological study PIK3R1 BTK 1
dasatinib, temozolomide, placebo, radiation therapy PIK3R1 ABL1 1
dasatinib, temozolomide, placebo, radiation therapy PIK3R1 BTK 1
decitabine, gemcitabine PIK3R1 DNMT1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.